Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 94
Selected: 0
NCT IDTitle
NCT03732703Myeloma-Developing Regimens Using Genomics (MyDRUG)
NCT03071276Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT05177276Selinexor Combination Ph 1 Study
NCT02831686A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma
NCT07479979Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
NCT02530476Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
NCT02120222Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery
NCT04562870A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis
NCT07447817Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
NCT04782687Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
NCT05530421Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
NCT04256707Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment
NCT04562389Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis
NCT02384850Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
NCT02431351Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
NCT04914845KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia
NCT01607905Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
NCT04355676Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19
NCT04984330Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
NCT02649790Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
NCT04856189Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
NCT04768881Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
NCT02088541Selinexor (KPT-330) in Older Patients With Relapsed AML
NCT01896505A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma
NCT03110562Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
NCT05170789Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
NCT02314247Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
NCT04854434A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
NCT03880123Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma
NCT02249091A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT02212561Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome
NCT02606461Selinexor in Advanced Liposarcoma
NCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
NCT04421378A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
NCT04607772Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
NCT06399640Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
NCT02343042Selinexor and Backbone Treatments of Multiple Myeloma Patients
NCT02078349Phase I Study of KPT330 in Asian Patients
NCT02091245Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT02336815Selinexor Treatment of Refractory Myeloma
NCT02628704Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
NCT02213133Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas
NCT03042819Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
NCT03191981Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma
NCT05611931Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT02146833SHIP (Selinexor in Hormone Insensitive Prostate Cancer)
NCT05028348A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
NCT02416908Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
NCT05820763Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant